Pterine

Pterine

SCHEMBL702492

Nc1nc(=O)c2nccnc2[nH]1.[Mo]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 2/20 0.40
LMNA P02545 1/20 0.40
GLA P06280 1/20 0.40
PMP22 Q01453 1/20 0.40
CYP3A4 P08684 1/20 0.35
BLM P54132 1/20 0.35
PNP P00491 3/20 0.34
CCNB2 O95067 4/20 0.33
CDK1 P06493 4/20 0.33
CCNB1 P14635 4/20 0.33
GSK3A P49840 4/20 0.33
GSK3B P49841 4/20 0.33
CCNB3 Q8WWL7 4/20 0.33
CDK5 Q00535 3/20 0.33
CDK5R1 Q15078 3/20 0.33
HPGD P15428 2/20 0.33
USP2 O75604 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pterine SCHEMBL64321 0.98 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10LMNAGLA
Pterine SCHEMBL5703599 0.96 ALDH1A1 (0.40) ALDH1A1KDM4EHSD17B10LMNAGLA
Pterine SCHEMBL27339748 0.96 ALDH1A1 (0.40) ALDH1A1KDM4EHSD17B10LMNAGLA
Pterine SCHEMBL906055 0.96 ALDH1A1 (0.40) ALDH1A1KDM4EHSD17B10LMNAGLA
Pterine SCHEMBL27566960 0.96 ALDH1A1 (0.40) ALDH1A1KDM4EHSD17B10LMNAGLA
Pterine SCHEMBL29287280 0.96 ALDH1A1 (0.40) ALDH1A1KDM4EHSD17B10LMNAGLA
Pterine SCHEMBL27866244 0.96 ALDH1A1 (0.40) ALDH1A1KDM4EHSD17B10LMNAGLA
Pterine SCHEMBL29205870 0.91 ALDH1A1 (0.37) ALDH1A1KDM4EHSD17B10LMNAGLA
Pterine SCHEMBL28301534 0.84 ALDH1A1 (0.36) ALDH1A1KDM4EHSD17B10LMNAGLA
SCHEMBL7682920 0.73 KDM4E (0.47) ALDH1A1KDM4EHSD17B10LMNAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3688169-A2 GENETIC KNOCKOUTS IN WOOD-LJUNGDAHL MICROORGANISMS Lanzatech, Inc. (US) 2020-08-05 EP disclosed
US-20200239896-A1 GENETIC KNOCKOUTS IN WOOD-LJUNGDAHL MICROORGANISMS LANZATECH, INC. 2020-07-30 US disclosed
WO-2019068011-A2 GENETIC KNOCKOUTS IN WOOD-LJUNGDAHL MICROORGANISMS LANZATECH, INC. (US) 2019-04-04 WO disclosed
US-20160289278-A1 GENES OF AN OTITIS MEDIA ISOLATE OF NONTYPEABLE HEAMOPHILUS INFLUENZAE NATIONWIDE CHILDREN'S HOSPITAL 2016-10-06 US disclosed
US-9102729-B2 Polypeptides from non-typeable Haemophilus influenzae NOVARTIS VACCINES AND DIAGNOSTICS SRL (US) 2015-08-11 US disclosed
US-20150218231-A1 GENES OF AN OTITIS MEDIA ISOLATE OF NONTYPEABLE HEAMOPHILUS INFLUENZAE NATIONWIDE CHILDREN'S HOSPITAL 2015-08-06 US disclosed
US-9034642-B2 Genes of an otitis media isolate of nontypeable Haemophilus influenzae NATIONWIDE CHILDREN'S HOSPITAL (US) 2015-05-19 US disclosed
US-20140234363-A1 POLYPEPTIDES FROM NON-TYPEABLE HAEMOPHILUS INFLUENZAE NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2014-08-21 US disclosed
US-20140127221-A1 Genes of an Otitis Media Isolate of Nontypeable Haemophilus Influenzae NATIONWIDE CHILDREN'S HOSPITAL, INC. (US) 2014-05-08 US disclosed
US-8652773-B2 Genes of an otitis media isolate of nontypeable Haemophilus influenza NATIONWIDE CHILDREN'S HOSPITAL, INC. (US) 2014-02-18 US disclosed
US-7749518-B2 Viral protein for use in devloping vaccine for treatment and preventon of infection, vision, arthritic and respiratory system disorders NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2010-07-06 US disclosed
EP-2070945-A1 Genes of an otitis media isolate of nontypeable haemophilus influenzae Nationwide Children's Hospital, Inc. (US) 2009-06-17 EP disclosed
US-20080267966-A1 Viral protein for use in devloping vaccine for treatment and preventon of infection, vision, arthritic and respiratory system disorders GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2008-10-30 US disclosed
US-7390937-B2 Plants with enhanced levels of nitrogen utilization proteins in their root epidermis and uses thereof THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2008-06-24 US disclosed
US-20050131222-A1 Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof HUMAN GENOME SCIENCES, INC. (US) 2005-06-16 US disclosed
US-20050044585-A1 Promoter element exhibits stress inducible expression; fungal nitrate reductases, mutant nitrate reductases lacking post-translational regulation, glutamate synthetase/dehydrogenase, aminotransferases, nitrate transporters, ammonia transporters and amino acid transporters THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2005-02-24 US disclosed
US-6846651-B2 Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof HUMAN GENOME SCIENCES, INC. (US) 2005-01-25 US disclosed
US-6528289-B1 Isolated polynucleotide; can be used in industrial fermentation and pharmaceutical development HUMAN GENOME SCIENCES, INC. 2003-03-04 US disclosed
US-6506581-B1 Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof HUMAN GENOME SCIENCE, INC. 2003-01-14 US disclosed
WO-2001055405-A1 A NOVEL POLYPEPTIDE, A HUMAN MOLYBDENUM PTERIN OXIDE-REDUCTASE 10 AND THE POLYNUCLEOTIDE ENCODING THE POLYPEPTIDE BIODOOR GENE TECHNOLOGY LTD. SHANGHAI (CN) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140234363-A1 POLYPEPTIDES FROM NON-TYPEABLE HAEMOPHILUS INFLUENZAE NGLY1, ANPEP, NT5E ALDH1A1 4468/4885KDM4E 4817/4885HSD17B10 4240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.